[go: up one dir, main page]

WO2000030668A8 - Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire - Google Patents

Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire

Info

Publication number
WO2000030668A8
WO2000030668A8 PCT/IB1999/002112 IB9902112W WO0030668A8 WO 2000030668 A8 WO2000030668 A8 WO 2000030668A8 IB 9902112 W IB9902112 W IB 9902112W WO 0030668 A8 WO0030668 A8 WO 0030668A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
parvovirus capsid
migration
inhibition
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1999/002112
Other languages
English (en)
Other versions
WO2000030668A3 (fr
WO2000030668A9 (fr
WO2000030668A2 (fr
Inventor
Kristina Broliden
Magnus Westgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99968407A priority Critical patent/EP1131085A2/fr
Priority to AU25666/00A priority patent/AU2566600A/en
Priority to MXPA01004949A priority patent/MXPA01004949A/es
Priority to JP2000583551A priority patent/JP2003516927A/ja
Priority to KR1020017006374A priority patent/KR20010080518A/ko
Priority to HU0104298A priority patent/HUP0104298A2/hu
Priority to CA002352043A priority patent/CA2352043A1/fr
Application filed by Individual filed Critical Individual
Publication of WO2000030668A2 publication Critical patent/WO2000030668A2/fr
Publication of WO2000030668A8 publication Critical patent/WO2000030668A8/fr
Publication of WO2000030668A3 publication Critical patent/WO2000030668A3/fr
Publication of WO2000030668A9 publication Critical patent/WO2000030668A9/fr
Priority to IS5931A priority patent/IS5931A/is
Priority to NO20012534A priority patent/NO20012534L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne la découverte de méthodes et de compositions permettant d'inhiber la croissance et/ou la migration de cellules porteuses de l'antigène P, notamment, entre autres, les cellules d'origine hématopoïétique et des cellules endothéliales. L'invention concerne, en particulier, l'utilisation de particules de capsides de parvovirus ou de fragments de protéines de capsides de parvovirus dans la fabrication de médicaments susceptibles d'être administrés à un patient dans le but d'inhiber la croissance des progéniteurs hématopoïétiques (par exemple, avant transplantation de cellules souches), la croissance des cellules endothéliales (par exemple, en tant que traitement anti-tumorigenèse ou pour empêcher la resténose ou l'accumulation de fibres après implantation d'une prothèse) ou pour empêcher les troubles impliquant la prolifération anormale de cellules porteuses de l'antigène P (par exemple, la polyglobuline essentielle).
PCT/IB1999/002112 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire Ceased WO2000030668A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP99968407A EP1131085A2 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
AU25666/00A AU2566600A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
MXPA01004949A MXPA01004949A (es) 1998-11-24 1999-11-23 Uso de particulas de capside de parvovirus en la inhibicion de la proliferacion y la migracion celular.
JP2000583551A JP2003516927A (ja) 1998-11-24 1999-11-23 細胞増殖および移動の抑制におけるパルボウイルスキャプシド粒子の使用
KR1020017006374A KR20010080518A (ko) 1998-11-24 1999-11-23 세포 증식 및 세포 이동의 억제에 대한 파르보바이러스캡시드 입자의 용도
HU0104298A HUP0104298A2 (hu) 1998-11-24 1999-11-23 Parvovíruskapszid-részecskék alkalmazása a sejtproliferáció és -migráció gátlására
CA002352043A CA2352043A1 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
IS5931A IS5931A (is) 1998-11-24 2001-05-02 Notkun smáveiruhjúphluta til að hamla frumufjölgun og frumuflutningi
NO20012534A NO20012534L (no) 1998-11-24 2001-05-23 Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804022A SE520177C2 (sv) 1998-11-24 1998-11-24 Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller
SE9804022-3 1998-11-24

Publications (4)

Publication Number Publication Date
WO2000030668A2 WO2000030668A2 (fr) 2000-06-02
WO2000030668A8 true WO2000030668A8 (fr) 2000-09-14
WO2000030668A3 WO2000030668A3 (fr) 2000-11-09
WO2000030668A9 WO2000030668A9 (fr) 2001-04-05

Family

ID=20413393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/002112 Ceased WO2000030668A2 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire

Country Status (14)

Country Link
EP (1) EP1131085A2 (fr)
JP (1) JP2003516927A (fr)
KR (1) KR20010080518A (fr)
CN (1) CN1328469A (fr)
AU (1) AU2566600A (fr)
CA (1) CA2352043A1 (fr)
CZ (1) CZ20011369A3 (fr)
HU (1) HUP0104298A2 (fr)
IS (1) IS5931A (fr)
MX (1) MXPA01004949A (fr)
NO (1) NO20012534L (fr)
PL (1) PL348640A1 (fr)
SE (1) SE520177C2 (fr)
WO (1) WO2000030668A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275658B1 (fr) * 2001-07-10 2006-11-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composé d'une variante de protéine VP1 de parvovirus et d'une protéine NS1 de parvovirus pour l'induction de cytolyse
EP1791858B1 (fr) * 2004-09-24 2010-04-21 Intercell AG Proteine de capside vp1 modifiee du parvovirus b19
CN101475942B (zh) * 2008-11-28 2012-05-23 中国人民解放军第四军医大学 一种b19病毒vp1独特区基因
US9598468B2 (en) 2011-05-18 2017-03-21 University Of Florida Research Foundation, Incorporated Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92298A (en) * 1988-11-14 2001-04-30 Us Secretary U S Dept Of Comme Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids
NL8902301A (nl) * 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.

Also Published As

Publication number Publication date
MXPA01004949A (es) 2003-03-10
CN1328469A (zh) 2001-12-26
SE520177C2 (sv) 2003-06-03
WO2000030668A3 (fr) 2000-11-09
NO20012534D0 (no) 2001-05-23
WO2000030668A9 (fr) 2001-04-05
CZ20011369A3 (cs) 2001-10-17
IS5931A (is) 2001-05-02
CA2352043A1 (fr) 2000-06-02
JP2003516927A (ja) 2003-05-20
WO2000030668A2 (fr) 2000-06-02
SE9804022D0 (sv) 1998-11-24
EP1131085A2 (fr) 2001-09-12
AU2566600A (en) 2000-06-13
HUP0104298A2 (hu) 2002-03-28
KR20010080518A (ko) 2001-08-22
PL348640A1 (en) 2002-06-03
NO20012534L (no) 2001-06-29
SE9804022L (sv) 2000-05-25

Similar Documents

Publication Publication Date Title
Deng et al. Bioceramic scaffolds with antioxidative functions for ROS scavenging and osteochondral regeneration
Murata et al. Acid‐insoluble human dentin as carrier material for recombinant human BMP‐2
Lynn et al. Temporal progression of the host response to implanted poly (ethylene glycol)‐based hydrogels
WO1999046366A8 (fr) Utilisations de cellules souches humaines mesenchymateuses non autologues
AU4221399A (en) Human cd45+ and/or fibroblast + mesenchymal stem cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
AU4035199A (en) Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation
NZ527565A (en) Methods and devices for tissue repair
YU57701A (sh) Veštački peptidi koji imaju površinsku aktivnost i njihova upotreba u pripremi veštačkog surfaktanta
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
WO2003068149A3 (fr) Preparations de cellules du nucleus pulposus et procedes permettant leur generation, identification, et utilisation
WO2002069988A3 (fr) Compositions contenant des cellules de moelle osseuse ainsi qu'une matrice osseuse demineralisee et/ou mineralisee et leur utilisation dans la transplantation de moelle osseuse
IL115473A (en) Pharmaceutical compositions and compounds for inhibition of stem cell proliferation, use of such compounds in the manufacture of medicaments for this purpose, and in vitro methods for treating bone marrow and for preparing hematopoietic cells for therapy
DE69726759D1 (de) Cytopatische viren zur therapie und prophylaxe der neoplasie
AU2901899A (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
DK1451302T3 (da) In vitro rekonstituerede lag af humant hornhindeepitel samt fremgangsmåde til fremstilling deraf
Rakonczay Jr et al. Chronic inflammation in the pancreas and salivary glands-lessons from similarities and differences in pathophysiology and treatment modalities
WO2000030668A8 (fr) Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
ATE209502T1 (de) Flüssigkristalle des cyclosporins
WO2001070290A3 (fr) Microspheres injectables destinees a la construction de tissus
WO2021173928A3 (fr) Variants d'alpha-galactosidase humaine
Yuan et al. Chondrogenic differentiation and immunological properties of mesenchymal stem cells in collagen type I hydrogel
KR102121602B1 (ko) 지방줄기세포배양용 배지 조성물 제조방법, 지방줄기세포배양용 배지 조성물 제조방법과 줄기세포 유효성분 3저 추출법을 이용한 줄기세포파쇄추출물(쉘드줄기세포) 제조방법, 이를 이용한 항관절염 치료용 조성물, 이를 이용한 염증억제 효과를 갖는 조성물 및 세포재생 효과를 갖는 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813653.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1; PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 142602

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-1369

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 511402

Country of ref document: NZ

Ref document number: 25666/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004949

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017006374

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2352043

Country of ref document: CA

Ref document number: 2352043

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 583551

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999968407

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017006374

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999968407

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1369

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-1369

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017006374

Country of ref document: KR